Top Stock Market Gainers: Bowman, Varex, MarineMax, and Aligos Surge

• Bowman Consulting Group led the group after agreeing to be acquired by Bernhard Capital Partners for $43.00 per share in cash.
• Varex Imaging Corporation surged following Teledyne Technologies’ agreement to acquire the company for approximately $1.1 billion.
• MarineMax recorded a substantial gain after entering an all-cash acquisition agreement with Safe Harbor Marinas.
• Aligos Therapeutics advanced following its recently released second-quarter 2026 financial results.

Several companies recorded major stock market gains today, supported primarily by acquisition announcements and recent financial results.

Bowman Consulting Group Ltd. (NASDAQ: BWMN) gained 55.78%, with its stock rising $15.19 to $42.42. The engineering and program management firm entered into a definitive agreement to be acquired by Bernhard Capital Partners for $43.00 per share in cash. The transaction represents an enterprise value of approximately $1 billion and a 58% premium to Bowman’s closing price of $27.23 on August 7, 2026.

Varex Imaging Corporation (NASDAQ: VREX) shares increased 48.75% to $18.46. The company manufactures X-ray imaging components and related software used in medical, industrial, and security applications. The rally followed Teledyne Technologies’ announcement that it would acquire Varex for $18.90 per share in cash, valuing the transaction at approximately $1.1 billion. The deal is expected to close in early 2027, subject to shareholder and regulatory approvals.

MarineMax, Inc. (NYSE: HZO) rose 46.08% to $52.12. The surge followed the announcement of an agreement under which Safe Harbor Marinas, a Blackstone Infrastructure portfolio company, will acquire MarineMax for $53.00 per share in cash. The transaction is valued at approximately $1.5 billion, including debt, and is expected to close by the end of 2026, subject to shareholder and regulatory approvals.

Aligos Therapeutics, Inc. (NASDAQ: ALGS) recorded a 36.85% gain, with its stock increasing $2.06 to $7.65. The clinical-stage biopharmaceutical company develops treatments for liver and viral diseases. Aligos released its second-quarter 2026 results on August 6, reporting approximately $27.8 million in license revenue and a net loss of $1.5 million, or $0.14 per share. The company also provided updates on its clinical programs and recently announced licensing agreement with Amoytop.

In summary, today’s market gains were driven largely by significant merger and acquisition activity. Bowman Consulting Group, Varex Imaging, and MarineMax all rallied after announcing all-cash acquisition agreements, while Aligos Therapeutics advanced following its recently released second-quarter financial results.